程序性死亡受体配体1（PD-L1）和细胞毒性T淋巴细胞相关抗原4（CTLA-4）在女性尿道癌中的表达。
Expression of PD-L1 and CTLA-4 in female urethral carcinoma.
作者信息
Ninomiya Sahoko, Kawahara Takashi, Mochizuki Taku, Ishiguro Yukari, Miyoshi Yasuhide, Otani Masako, Yao Masahiro, Miyamoto Hiroshi, Uemura Hiroji
机构信息
Departments of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Kanagawa Japan.
Division of Diagnostic Pathology Yokohama City University Medical Center Yokohama Kanagawa Japan.
出版信息
IJU Case Rep. 2018 Nov 23;2(1):23-26. doi: 10.1002/iju5.12029. eCollection 2019 Jan.
INTRODUCTION
Although the tumors are often easily detected, a considerable number of patients with female urethral carcinoma are diagnosed in an advance stage. Thus, no evidence-based therapeutic approach has been established. We herein report our experience in the treatment of three female patients with urethral carcinoma. We also examined the expression of PD-L1 and CTLA-4.
CASE PRESENTATION
Three female patients pathologically diagnosed with urethral carcinoma, including urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma, between 2013 and 2017 were analyzed in this study. Two patients underwent urethrectomy with cystostomy. Immunohistochemistry was performed to assess the levels of PD-L1 and CTLA-4 expression in patients with urethral carcinoma. Eleven control cases of urethral carcinoma tissue were also stained.
CONCLUSION
This study revealed the expression of PD-L1 and CTLA-4 in female urethral carcinomas.
引言
尽管肿瘤通常易于检测，但相当数量的女性尿道癌患者在晚期才被诊断出来。因此，尚未建立基于证据的治疗方法。我们在此报告我们治疗三名女性尿道癌患者的经验。我们还检测了程序性死亡受体1（PD-L1）和细胞毒性T淋巴细胞相关蛋白4（CTLA-4）的表达情况。
病例介绍
本研究分析了2013年至2017年间经病理诊断为尿道癌的三名女性患者，包括尿路上皮癌、鳞状细胞癌和腺癌。两名患者接受了尿道切除术及膀胱造瘘术。采用免疫组织化学法评估尿道癌患者中PD-L1和CTLA-4的表达水平。同时对11例尿道癌组织对照病例进行了染色。
结论
本研究揭示了PD-L1和CTLA-4在女性尿道癌中的表达情况。
Zotero 插件